Kamada (KMDA) Change in Accured Expenses (2012 - 2026)
Kamada (KMDA) posted quarterly Change in Accured Expenses of -$1.9 million for Q1 2026, up 7.19% year-on-year from -$1.8 million in Q1 2025, and down 257.69% on a QoQ basis from $1.2 million in Q4 2025.
Kamada (KMDA) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Change in Accured Expenses for 15 consecutive years, with -$1.9 million the latest figure, recorded in Q1 2026.
- Quarterly Change in Accured Expenses rose 7.19% year-over-year to -$1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 22.75% YoY) and the FY2025 annual result came in at $950000.0, down 32.77% from the prior year.
- Change in Accured Expenses declined to -$1.9 million in Q1 2026 per KMDA's latest filing, from $1.2 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for KMDA reached as high as $1.6 million in Q4 2024 and fell as low as -$2.1 million in Q1 2024.
- A 5-year average of -$2731.2 and a median of $2083.0 in 2022 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 407346.38% — and 2024, when it slumped 861664.71%.
- Year by year, Change in Accured Expenses stood at -$276.0 in 2022, then soared by 407346.38% to $1.1 million in 2023, then jumped by 39.68% to $1.6 million in 2024, then fell by 23.38% to $1.2 million in 2025, then tumbled by 257.69% to -$1.9 million in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.9 million, $1.2 million, and $630000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.01 Bn | 20.86 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 22.02 Bn | 22.02 Bn | - | - |
| 7 | Viatris | 20.40 Bn | 18.59 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.74 Bn | 12.31 Bn | 785.00 Mn | - |
| 10 | Kamada | 399.49 Mn | 326.34 Mn | 19.12 Mn | -1.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.90 Mn |
| Mar 31, 2026 | -1.90 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 630,000.00 |
| Sep 30, 2025 | 630,000.00 |
| Jun 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 1.16 Mn |
| Mar 31, 2025 | -2.04 Mn |
| Mar 31, 2025 | -2.04 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 881,000.00 |
| Sep 30, 2024 | 881,000.00 |
| Jun 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Dec 31, 2023 | 1.12 Mn |
| Dec 31, 2023 | 1.12 Mn |